| Literature DB >> 32460869 |
Elodie Miquelestorena-Standley1,2, Charlotte Jaulerry3,4, Marie-Christine Machet5,3, Nolwenn Rabot4, Christelle Barbet4, Aurélie Hummel6, Alexandre Karras7, Cyril Garrouste8, Thomas Crepin9, Didier Ducloux9, Maud Cousin10, Catherine Albert11, Joseph Rivalan12, Emilie Cornec-Le Gall13, François Pourreau14, Clément Deltombe15, Dominique Nochy16, Nora Szlavik17, Sophie Felix18, Anne Croué19, David Buob20, Nathalie Rioux-Leclerc21, Laurent Doucet22, Jean-Michel Goujon23, Karine Renaudin24, Emmanuelle Blanchard3,25, Sébastien Eymieux3,25, Marion Rabant26, Jean-Michel Halimi3,4.
Abstract
BACKGROUND: Infection-related glomerulonephritis with IgA deposits (IRGN-IgA) is a rare disease but it is increasingly reported in the literature. Data regarding epidemiology and outcome are lacking, especially in Europe. We aimed to assess the clinical, pathologic and outcome data of IRGN-IgA.Entities:
Keywords: Diabetes; IgA; Infection; Kidney; Staphylococcus
Mesh:
Year: 2020 PMID: 32460869 PMCID: PMC7254713 DOI: 10.1186/s13000-020-00980-6
Source DB: PubMed Journal: Diagn Pathol ISSN: 1746-1596 Impact factor: 2.644
Demographics, predisposing factors to infection and infectious history
| Variables | |
|---|---|
| 23 (85.2) | |
| 62 ± 15 | |
| Diabetes mellitus (n (%)) | 12/27 (44.4) |
| Hypertension (n (%)) | 18/26 (69.2) |
| Cardiovascular disease (n (%)) | 13/25 (52.0) |
| Active or former smokers (n (%)) | 11/25 (44.0) |
| Alcoholism (n (%)) | 9/24 (37.5) |
| Liver cirrhosis (n (%)) | 2/22 (9.1) |
| Immunosuppressive drug (n (%)) | 1/27 (3.7) |
| 21 (77.8) | |
| MRSA (n (%)) | 4 (14.8) |
| MSSA (n (%)) | 16 (59.3) |
| 1 (3.7) | |
| 2 (7.4) | |
| 1 (3.7) | |
| 1 (3.7) | |
| 1 (3.7) | |
| 1 (3.7) | |
| 1 (3.7) | |
| 1 (3.7) | |
| 1 (3.7) | |
| More than one pathogen (n (%)) | 7 (25.9) |
| Unknown (n (%)) | 3 (11.1) |
| Bone and joint infection (n (%)) | 12 (44.4) |
| Skin infection (n (%)) | 11 (40.7) |
| Bacteremia (n (%)) | 11 (40.7) |
| Other sites | |
| Prosthesis, plate osteosynthesis or implantable venous access port (n (%)) | 5 (18.5) |
| Endocarditis (n (%)) | 4 (14.8) |
| Pneumonia (n (%)) | 4 (14.8) |
| Urinary tract infection (n (%)) | 3 (11.1) |
Abbreviations: ESBL extended-spectrum beta-lactamases, MRSA methicillin-resistant Staphylococcus aureus, MSSA methicillin-sensitive Staphylococcus aureus, standard deviation
Renal presentation
| Nephrotic syndrome (n (%)) | 18/27 (66.7) |
| Acute nephritic syndrome (n (%)) | 15/27 (55.6) |
| Rapidly progressive glomerulonephritis (n (%)) | 15/27 (55.6) |
| Hematuria (n (%)) (microscopic/macroscopic) | 20/21 (95.2) (11/8) |
| Serum creatinine, mg/dL (mean ± SD) | 4.24 ± 2.93 |
| Creatinine > 4 mg/dL (n (%)) | 13/27 (48.1) |
| eGFR, mL/min/1.73m2 (mean ± SD (range)) | 23.7 ± 19.9 (3–82) |
| Albumin, g/L (mean ± SD (range)) | 24.7 ± 7.4 (15–42) |
| Proteinuria, g/day (mean ± SD) | 5 ± 3.4 (0.4–16.4) |
| Baseline serum creatinine, mg/dL (mean ± SD) | 1.06 ± 0.3 |
| Low C4 levels (n (%)) | 2/26 (7.7) |
| Low C3 levels (n (%)) | 4/25 (16.0) |
| Both C3 and C4 low levels (n (%)) | 2/25 (8.0) |
| High serum IgA levels (n (%)) | 11/13 (84.6) |
| ANCA (n (%)) | 4/15 (26.7) |
Abbreviations: ANCA antineutrophil cytoplasmic antibodies, eGFR estimated glomerular filtration rate, SD standard deviation
Microscopy findings
| Variables | n = 27 |
|---|---|
| 15 ± 9 (3–46) | |
| 2 ± 2 (0–8) | |
| 24 (88.9) | |
| 24 (88.9) | |
| Segmental (n (%))/Global (n (%)) | 9 (33.3)/15 (55.6) |
| Focal (n (%))/Diffuse (n (%)) | 10 (37.0)/14 (51.9) |
| 22 (81.4) | |
| < 5 neutrophils per glomerulus (n (%))/≥5 neutrophils per glomerulus (n (%)) | 15 (55.5)/7 (25.9) |
| 9 (33.3) | |
| 10 (37.0) | |
| 7 (25.9%)/5 (18.5%)/0 | |
| 3 (11.1) | |
| 16 (59.2) | |
| Subepithelial humps (n (%))/Intramembranous (n (%)) | 13 (48.1)/3 (11.1) |
| 23 (85.1) | |
| Mild (n (%))/Moderate (n (%))/Severe (n (%)) | 12 (44.4)/5 (18.5)/6 (22.2) |
| 21 (77.8) | |
| Mild (n (%))/Moderate (n (%))/Severe (n (%)) | 16 (59.3)/5 (18.5)/0 |
| 23 (85.1) | |
| Mild (n (%))/Moderate (n (%))/Severe (n (%)) | 8 (29.6)/8 (29.6)/7 (25.9) |
| 18 (66.7) | |
| 24 (88.9) | |
| Mild (n (%))/Moderate (n (%))/Severe (n (%)) | 4 (14.8)/16 (59.3)/4 (14.8) |
| 7 (25.9) | |
| 17 (63.0) | |
| 3 (11.1) | |
Abbreviations: SD standard deviation
Fig. 1Microscopy. a: mesangial with endocapillary proliferation was the most frequent pattern (Jones silver stain × 300); b: exudative endocapillary proliferation (PAS stain × 200); c: membranoproliferative glomerulonephritis (Jones silver stain × 200); d: crescentic proliferation with fibrinoid necrosis (Jones silver stain × 300); e: subepithelial humps deposit (electron microscopy × 20.000); f: subendothelial deposits with hyaline thrombus resembling cryoglobulin (arrow) (Masson’s trichrome stain × 1000)
Immunofluorescence and immunohistochemistry findings
| Immunofluorescence | |
|---|---|
| IgA | 27/27 (100) |
| +/ ++ / +++ (n (%)) | 8 (29.6)/9 (33.3)/10 (37.1) |
| Mesangial/Capillary loop/Both (n (%)) | 9 (34.6)/5 (19.2)/12 (46.2) |
| C3 | 27/27 (100) |
| +/++/+++ (n, %) | 5 (19.2)/6 (23.1)/15 (57.7) |
| Mesangial/Capillary loop/Both (n (%)) | 9 (36.0)/2 (8.0)/14 (56.0) |
| IgA and C3 codominant (n (%)) | 15 (55.5) |
| IgA dominant (n (%)) | 3 (11.1) |
| IgG staining (n (%)) | 4/27 (14.8) |
| IgM (n (%)) | 6/27 (22.2) |
| C1q (n (%)) | 0 |
| Kappa (n (%)) | 9/24 (37.5) |
| Lambda (n (%)) | 14/24 (58.3) |
| 23/27 (85.2) | |
| 0/+/++ (n (%)) | 8 (34.8)/11 (47.8)/4 (17.4) |
Fig. 2Infection-to-biopsy delay and immunofluorescence according to histologic pattern. a: Delay in days between documentation of infection and renal biopsy according to histologic pattern; b: IgA intensity staining according to histologic pattern; c: C3 intensity staining according to histologic pattern. Values are expressed as median and interquartile range. Abbreviations: GN: glomerulonephritis
Outcome and prognostic factors (25 patients)
| eGFR > 60 mL/min/1.73m2 a | PRD b | ESRD c | ||
|---|---|---|---|---|
| 7 | 14 | 4 | ||
| 28 | 56 | 16 | ||
| 61 | 64 | 68 | 0.8 | |
| 8.3 | 16.5 | 21.6 | 0.3 | |
| Mean eGFR, ml/min/1.73m2 | ||||
| At biopsy | 28.9 | 20.9 | 17.5 | 0.6 |
| Follow-up | 84.6 | 37.5 | – | |
| Mean proteinuria at biopsy, g/day | 3.5 | 5.5 | 6.5 | 0.2 |
| Corticosteroids, % of patients | 0 | 64 | 25 | |
| Median infection-renal injury delay, days (IQR) | 13 (8.5–36) | 23 (17.8–69) | 13 (10–47.3) | 0.3 |
| Histologic pattern (acute/subacute/resolving, %) | 29/57/14 | 29/64/7 | 50/25/25 | 0.1 |
| Global glomerulosclerosis, % of glomeruli | 13 | 18 | 44 | 0.2 |
| Crescentic proliferation, % of glomeruli | 4 | 6 | 5 | 0.9 |
| Interstitial inflammation score, mean | 0.9 | 0.9 | 1.5 | 0.2 |
| Acute tubular injury score, mean | 1.6 | 1.8 | 1.75 | 0.8 |
| IF/TA score, mean | 0.9 | 1.6 | 2.5 | |
| Arteriosclerosis, mean | 2 | 1.8 | 2 | 0.6 |
Abbreviations: eGFR estimated glomerular filtration rate, ESRD end-stage renal disease, IF/TA interstitial fibrosis with tubular atrophy, IQR interquartile ranges, PRD persistent renal disease (eGFR< 60 ml/min/1.73m2)
aOne patient with eGFR> 60 died; bOne patient with PRD died; cTwo patients with ESRD died